N
News Analysis
prnewswire.com

www.prnewswire.com ·

Negative

investor alert pomerantz law firm investigates claims on behalf of investors of grace therapeutics inc grce 302773100

WB_406_COMPETITION_POLICYWB_2101_ANTITRUSTEPU_CATS_REGULATIONTRIAL

All NewsRead the full story on prnewswire.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Single-company-specific: Grace Therapeutics faces FDA rejection for its NDA for GTx-104 due to packaging/manufacturing issues. This directly impacts the company's revenue prospects (no approval, no sales) and margin (additional compliance costs). No broader sector or supply chain impact beyond this firm.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Grace Therapeutics (GRCE) received a Complete Response Letter from FDA for GTx-104 on April 23, 2026.
  • Stock price dropped 45.48% ($1.96) to $2.35 per share on the same day.
  • Issues cited: product packaging and manufacturing deficiencies.
  • Pomerantz LLP is investigating potential securities fraud or unlawful business practices.

About the publisher

prnewswire.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

prnewswire.com files this story under "wb 406 competition policy" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

investor alert pomerantz law firm investigates claims on behalf of investors of grace therapeutics inc grce 302773100 | prnewswire.com — News Analysis